DR. PAUL L HUANG, MD PHD
Osteopathic Medicine at Fruit St, Boston, MA

6630347, Oct 7, 2003

Oct 20, 2000

09/692056

Paul L. Huang - Boston MA
Mark C. Fishman - Newton Center MA
Michael A. Moskowitz - Belmont MA

The General Hospital Corporation - Boston MA

C12N 500

435325, 435354, 435366, 435368, 435371, 435372, 435455, 435463

This invention relates to transgenic non-human animals comprising a disrupted endothelial nitric oxide synthase gene. These animals exhibit abnormal wound-healing properties and hypertension. This invention also relates to methods of using the transgenic animals to screen for compounds having a potential therapeutic utility for vascular endothelial disorders, such as hypertension, cerebral ischemia or stroke, atherosclerosis and wound-healing activities. Moreover, this invention also relates to methods of treating a patient suffering from hypertension and wound-healing abnormalities with the compounds identified using the transgenic animals, and methods of making the transgenic animals. A method of treating a wound using nitroglycerin is also provided.

8574635, Nov 5, 2013

Feb 16, 2011

12/932018

Sylvia Lee-Huang - New York NY, US
Paul L. Huang - Boston MA, US
Philip Lin Huang - Maple Glen PA, US
Dawei Zhang - Elmhurst NY, US
John Z. H. Zhang - New York NY, US
Young Tae Chang - New York NY, US
Jae Wook Lee - San Diego CA, US
Ju Bao - Brooklyn NY, US
Yongtao Sun - Xi'an, CN

New York University - New York NY
The General Hospital Corporation - Boston MA

A01N 65/00

424725

The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues.

2009006, Mar 5, 2009

Jul 9, 2007

11/827135

Sylvia Lee-Huang - New York NY, US
Paul L. Huang - Boston MA, US
Philip Lin Huang - Maple Glen PA, US
Dawei Zhang - Elmhurst NY, US
John Z.H. Zhang - New York NY, US
Young Tae Chang - New York NY, US
Jae Wook Lee - San Diego CA, US
Ju Bao - Brooklyn NY, US
Yongtao Sun - Chaanxi Province, CN

A61K 36/00, A61K 31/351, A61K 31/70, A61K 38/28, A61K 31/4439, A61K 31/435, A61K 31/366, A61K 31/7036, A61P 3/00, A61P 31/12, A61K 31/175, A61K 31/445, A61K 31/404, A61K 31/40, A61K 31/427, A61K 31/155, A61K 31/05

424774, 514460, 514734, 514 27, 514636, 514 4, 514369, 514342, 514423, 514277, 514419, 514635, 514634, 514331, 514 42, 514592

The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues.

5484889, Jan 16, 1996

Jul 21, 1994

8/277283

Sylvia Lee-Huang - New York NY
Philip L. Huang - Boston MA
Peter L. Nara - Frederick MD
Hao-Chia Chen - Potomac MD
Hsiang-fu Kung - Middletown MD
Peter Huang - New York NY
Henry I. Huang - New York NY
Paul L. Huang - Boston MA

New York University - New York NY
American Biosciences, Inc. - Boston MA
The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC

C07K 14415

530379

A protein, in particular MAP 30, obtainable from both the fruit and seeds of Momordica charantia or produced by recombinant means useful for treating tumors and HIV infections is disclosed. In treating HIV infections, the protein is administered alone or in conjunction with conventional AIDS therapies. Also provided are processes for purifying the protein, DNA sequences encoding the protein, and recombinant DNA methods for expressing the protein.

6310270, Oct 30, 2001

Mar 14, 1997

8/818082

Paul L. Huang - Boston MA
Mark C. Fishman - Newton Center MA
Michael A. Moskowitz - Belmont MA

The General Hospital Corporation - Boston MA

A01K 6700, A01K 67033, C12N 1500, G01N 3300

800 18

This invention relates to transgenic non-human animals comprising a disrupted endothelial nitric oxide synthase gene. These animals exhibit abnormal wound-healing properties and hypertension. This invention also relates to methods of using the transgenic animals to screen for compounds having a potential therapeutic utility for vascular endothelial disorders, such as hypertension, cerebral ischemia or stroke, atherosclerosis and wound-healing activities. Moreover, this invention also relates to methods of treating a patient suffering from hypertension and wound-healing abnormalities with the compounds identified using the transgenic animals, and methods of making the transgenic animals. A method of treating a wound using nitroglycerin is also provided.

7838275, Nov 23, 2010

Jul 9, 2001

10/487259

Sylvia Lee-Huang - New York NY, US
Philip L. Huang - Maple Glen PA, US
Paul Huang - Boston MA, US

New York University - New York NY

C12N 9/36, A61K 38/47

435206, 424 9461, 4241881, 424 946, 424 941, 435200, 435195, 435183

A fragment of lysozyme which contains a minimum nine amino acid sequence with antiviral, anti-tumor and bactericidal activities but lacking muramidase activity is provided. The invention also relates to pharmaceutical compositions containing this fragment and methods for treating HIV infection or for inhibiting tumor growth using this fragment as an active ingredient.

2013015, Jun 13, 2013

Jun 27, 2011

13/806348

Michael J. Cima - Winchester MA, US
Paul Huang - Boston MA, US
Yibo Ling - Brooklyn NY, US
Terrence Pong - San Francisco CA, US
Christophoros C. Vassiliou - Cambridge MA, US

The General Hospital Corporation - Boston MA
Massachusetts Institute of Technology - Cambridge MA

A61B 5/055

600420

An implantable magnetic relaxation sensor is provided that comprises superparamagnetic nanoparticies functionalized with one or more agents that bond with a biomarker of interest. The sensor is configured for minimally-invasive implantation into a human or animal, and is configured to indicate the implanted sensor's cumulative exposure to the biomarker of interest by analysis using magnetic resonance relaxometry.